Examples of Active Grants Since 2006
PI
Sponsor
Grant #
Start
Stop
Total
Awarded to
Date
______
01/05/04
01/04/06
$100,000
Fluorescence-Based High Throughput Screening for Novel
Calcium Entry Ligands to Control Human Disease: Novel
Therapeutics for Cystic Fibrosis and Diabetes Mellitus
Interactions of CFTR and Proton-Gated Na Channels
Title
SCHWIEBERT, ERIK M
UAB-SRI JOINT
RESEARCH PROJECT
INITIATIVE
JI, HONG-LONG
CYSTIC FIBROSIS
FOUNDATION
JI04GO
09/01/04
03/31/06
$113,085
CLANCY, JOHN PAUL
NIH-NHLBI
R01HL67088
05/03/01
04/30/06
$1,020,400
SCHWIEBERT, ERIK M
CYSTIC FIBROSIS
FOUNDATION
SCHWIE05P0
05/01/05
04/30/06
$75,000
Epithelial Zinc Receptors and Rescue of Respiratory CF
ROWE, STEVEN M
CYSTIC FIBROSIS
FOUNDATION
ROWE05D0
01/01/06
06/30/06
$26,597
Suppression of Premature Stop Mutations in CFTR
MATALON, SADIS
NIH-NHLBI
R01HL072871
09/30/02
07/31/06
$1,248,500
DELUCAS, LAWRENCE J.
CYSTIC FIBROSIS
FOUNDATION
DELUCA03GO
01/01/04
11/30/06
$453,017
Production of full-length CFTR Proteins
CLANCY, JOHN PAUL
THE RESEARCH
INSTITUTE (TRI)
CHILDREN'S HOSPITAL
BIRMINGHAM
01/01/05
12/31/06
$100,000
Matrix Metalloproteinases in Cystic Fibrosis Lung Disease
CLANCY, JOHN PAUL
CYSTIC FIBROSIS
SERVICES, INC. /
CHILDREN'S HOSPITAL &
REGIONAL MEDICAL
CENTER
OM003
(SCHEDULE 2.0)
02/01/04
12/31/06
$39,300
Assessment of Induced Sputum as a Tool to Evaluate Anti
Inflammatory Agents in Patients with Cystic Fibrosis; UAB Internal
Title: A Randomized Controlled Trial of anti-Inflammatory Agents
in patients with Cystic Fibrosis Using an Assessment of Induced
sputum as an Evaluation Tool
CLANCY, JOHN PAUL
EURAND, S.P.A. / PPD
DEVELOPMENT, LP
EUR-1008-M
03/17/06
03/16/07
$77,617
A Randomized, Double-Blind, Placebo-Controlled Two-Treatment,
Crossover Study to Evaluate the Safety and Efficacy of Eurand
Pancreatic Enzyme Product (PEP) in Patients with Cystic Fibrosis
and Exocrine Pancreatic Insufficiency
CLANCY, JOHN PAUL
EURAND, S.P.A. / PPD
DEVELOPMENT, LP
$5,820
An Open-Label Study to Evaluate the Safety and Efficacy of
Eurand Pancreatic Enzyme Produce (PEP) Microtabs ® in
Pediatric Patients with Cystic Fibrosis and Exocrine Pancreatic
Insufficiency
______
EUR-1009-M
03/17/06
03/16/07
2
Regulation of CFTR by Adenosine, A2 Receptors, and PLA2
Modulation of Innate Immunity in Lung Transplantation (includes
studies of CF individuals)
Examples of Active Grants Since 2006
PI
Sponsor
Grant #
Start
Stop
Total
Awarded to
Date
______
01/01/05
03/31/07
$189,605
Matrix Metalloproteinases: Mediators of Acute Lung Injury in
Children
Title
CLANCY, JOHN PAUL
THRASHER RESEARCH
FUND
CLANCY, JOHN PAUL
SALUS PHARMA / CORUS
PHARMA
CP-AI-0007
04/25/06
04/24/07
$37,328
A Phase 3, Double-Blind, Multicenter, Multinational, Randomized,
Placebo-Controlled Trial Evaluating Aztreoman Lysinate for
Inhalation in Cystic Fibrosis Patients with Pulmonary P.
aeruginosa (AIR-CFI)
BEBOK, ZSUZSANNA
PTC THERAPEUTICS,
INC.
PTC124-GD-003CF
01/30/06
04/30/07
$38,973
Morphologic studies following administration of new PTC
compounds as oral treatment for nonsense-mediated cystic
fibrosis
BEDWELL, DAVID M
NIH-NIGMS
R01GM68854
06/01/03
05/31/07
$1,137,207
FU, LIANWU (KARL) /
SZTUL, ELIZABETH
NIH-NIDDK
K01 068074
07/01/04
06/30/07
$288,036
Sorting of CFTR for Degradation
CLANCY, JOHN PAUL
INSPIRE
PHARMACEUTICALS, INC
08/07/06
08/06/07
$59,991
A Multicenter, Double-Blind, Placebo-controlled Randomized,
Efficacy and Safety study of Denufosol Tetrasodium (INS37217)
Inhalation Solution in Patients with Mild Cystic Fibrosis Lung
Disease
BENOS, DALE J
NIH-NIDDK
P50DK53090
09/01/02
08/31/07
$1,080,913
BEDWELL, DAVID M
NIH-NIDDK
P50DK53090
09/01/03
08/31/07
$553,906
Mechanistic Studies of CF Pathogenesis and CI Secretion - CF
Mouse Core
CLANCY, JOHN PAUL
CYSTIC FIBROSIS
FOUNDATION
______
09/01/06
08/31/07
$20,185
Examination of the metabolome of CFBE cell monolayers stably
transduced with lentivral cDNAs coding for wt CFTR, and
DF508CFTR compared with parental cells expressing
endogenous DF508 CFTR
KIRK, KEVIN L
NIH-NIDDK
P50DK53090
09/01/02
08/31/07
$1,080,913
SCHWIEBERT, ERIK M
NIH-NIDDK
P50DK53090
09/01/02
08/31/07
$218,633
Mechanistic Studies of CF Pathogenesis and CI Secretion - Core
B
SORSCHER, ERIC J
NIH-NIDDK
P50DK53090
09/01/02
08/31/07
$216,493
Mechanistic Studies of CF Pathogenesis and CI Secretion - Core
C
BEDWELL, DAVID M
NIH-NIDDK
P50DK53090
09/01/02
08/31/07
$1,080,913
3
Mechanism of Eukaryotic Translation Termination
Mechanistic Studies of CF Pathogenesis and CI Secretion Project 2
Mechanistic Studies of CF Pathogenesis and CI Secretion Project 1
Mechanistic Studies of CF Pathogenesis and CI Secretion Project 3
Examples of Active Grants Since 2006
Sponsor
Grant #
Start
Stop
Total
Awarded to
Date
CLANCY, JOHN PAUL
PTC THERAPEUTICS /
CHILDREN'S HOSPITAL
AND REGIONAL MEDICAL
CENTER
PTC124-GD-003CF
09/21/05
09/30/07
$215,050
A Phase 2 Study of PTC124 as an Oral Treatment for NonsenseMutation-Mediated Cystic Fibrosis
GUTIERREZ, HECTOR H
ALABAMA DEPARTMENT
OF PUBLIC HEALTH
C70119154
05/01/07
09/30/07
$23,285
Cystic Fibrosis Screening for Newborn Infants
CLANCY, JOHN PAUL
CYSTIC FIBROSIS
FOUNDATION /
UNIVERSITY OF NORTH
CAROLINA CHAPEL HILL
223265
05/07/04
12/01/07
$3,800
Genetic Modifiers in Cystic Fibrosis Lung Disease
GUTIERREZ, HECTOR H
GENENTECH, INC.
Z3877G
04/01/07
03/31/08
$28,462
A Multicenter, Randomized, Double-Blind, Placebo-Controlled
Trial of Pulmozyme ® Withdrawal on Exercise Tolerance in Cystic
Fibrosis Patients
ROWE, STEVEN M
NOVARTIS
PHARMACEUTICALS
CORPORATION
A two-part, randomized, double-blind, placebo-controlled,
ascending single-dose, adaptive study to evaluate safety,
tolerability, pharmacokinetics and pharmacodynamics of QAU145
administered via a nasal spray pump to patients with cystic fibrosis
PI
CLANCY, JOHN PAUL
BROUILLETTE, CHRISTIE
CHILDREN'S HOSPITAL &
REGIONAL MEDICAL
CENTER
UAB RESEARCH
FOUNDATION
Title
QAU145A2201
06/11/07
04/08/08
$174,693
412380260101UAB
07/01/07
06/30/08
$2,430
Antimicrobial resistance in sputum obtained from patients with
cystic fibrosis (CF)
______
08/02/06
09/23/08
$33,469
Testing of SGX/CFFT Proteins and Ligands
______
09/01/06
09/30/08
$120,000
Estrogen Sulfation in the Dysregulation of Hepatocyte Growth
Hormone Signaling in Cystic Fibrosis
10/01/07
09/30/08
$68,379
Cystic Fibrosis Screening for Newborn Infants
______
10/01/07
09/30/08
$20,313
Detection of CFTR in Airway Cells from CF Patients
Regulation of Epithelial Sodium channels by cGMP
FALANY, CHARLES
NAPOLEON
CYSTIC FIBROSIS
RESEARCH, INC.
GUTIERREZ, HECTOR H
ALABAMA DEPARTMENT
OF PUBLIC HEALTH
CLANCY, JOHN PAUL
VERTEX
PHARMACEUTICALS,
INC.
JI, HONG-LONG /
MATALON, SADIS
NIH-NHLBI
R01HL87017
01/01/07
01/31/09
$171,684
ROWE, STEVEN M
CYSTIC FIBROSIS
FOUNDATION
ROWE08AO
02/01/08
01/31/09
$2,700
Examination of the Metabolome of CF and non-CF Tissues from
Nasal Polyps
CLANCY, JOHN PAUL
GILEAD SCIENCES, INC.
CP-AI-0006
02/01/07
01/31/09
$45,503
A Phase 3, Open-Label, Follow-on Study of Multiple Courses of
Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients
(AIR-CF3)
C80117017
4
Examples of Active Grants Since 2006
PI
Sponsor
Grant #
Start
Stop
Total
Awarded to
Date
______
03/01/08
02/28/09
$20,000
Assay of Aminoglycosides in a CF Mouse Model
Title
BEDWELL, DAVID M
TECHNION - ISRAEL
INSTITUTE OF
TECHNOLOGY
CLANCY, JOHN PAUL
KALOBIOS
PHARMACEUTICALS,
INC.
KB001-03
03/01/08
02/28/09
$35,604
A Phase I/II Randomized, Double-Blind, Placebo-Controlled,
Single Dose, Dose Escalation Study of KB001-Cystic Fibrosis
Patients Infected with Pseudomonas Aeruginosa
GUTIERREZ, HECTOR H
UNIVERSITY OF
MASSACHUSETTS
(WORCHESTER)
337890
07/01/08
02/28/09
$4,000
The Effect of Formula Fortified with Docosahexaenoic Acid (DHA)
on Infants with Cystic Fibrosis
GUTIERREZ, HECTOR H
Cystic Fibrosis Foundation
Therapeutics,
Inc./Children's Hospital &
Regional Medical Center
EPIC002
(SCHEDULE 4.0)
11/11/04
03/31/09
$65,649
The EPIC Observational Study: Longitudinal Assessment of Risk
Factors for and Impact of Pseudomonas Aeruginosa Acquistion
and Early Anti-Pseudomonal Treatment in Children with CF
GUTIERREZ, HECTOR H
CYSTIC FIBROSIS
FOUNDATION
THERAPEUTICS, INC.
EPIC001
(SCHEDULE 3.0)
11/11/04
03/31/09
$40,357
Efficacy and Safety of Intermittent Animicrobial Therapy for the
Treatment of the New Onset Pseudomonas Aeruginosa Airway
Infection in Young Patients with Cystic Fibrosis
CLANCY, JOHN PAUL
CYSTIC FIBROSIS
FOUNDATION
CLANCY06A0
05/01/06
04/30/09
$390,494
Detection Of Airway CFTR Expression, Localization, and Activity
In CF Patients.
ROWE, STEVEN M
NIH-NIDDK
P30DK72482
05/01/07
04/30/09
$86,252
Pilot: Role of Flavonoids in CFTR Biogenesis and Activation
VX06-770-101
05/04/07
05/03/09
$77,686
A Phase II study of VX-770 in CF Subjects harboring G551D and
other surface localized CFTR mutations
YOTHER, JANET L
VERTEX
PHARMACEUTICALS,
INC. / PPD
DEVELOPMENT, LLC.
NIH-NHLBI
T32HL07553
07/01/03
06/30/09
$1,671,051
Basic Mechanisms in Lung Diseases
HAGOOD, JAMES
HRSA
T72MC00001
07/01/05
06/30/09
$1,352,427
Pediatric Pulmonary Center
GUIMBELLOT, JENNIFER
NIH-NIEMS
F30ES14987
07/15/06
07/14/09
$96,762
BENOS, DALE J
NIH-NIDDK
R01DK37206
08/01/03
07/31/09
$1,678,397
CLANCY, JOHN PAUL
TRANSAVE, INC.
TR02-106
09/30/07
08/30/09
$73,023
Multidose Safety and Tolerability Study of Dose Escalation of
Liposomal Amikacin for Inhalation (Arikace), in Cystic Fibrosis
Patients
GUTIERREZ, HECTOR H
ALABAMA DEPARTMENT
OF PUBLIC HEALTH
C90118098
10/01/08
09/30/09
$68,379
Cystic Fibrosis Screening for Newborn Infants
ROWE, STEVEN M
5
Effects of Ozone on CFTR Expression and HIF Signaling
Sodium Entry Into Amiloride-Sensitive Epithelia
Examples of Active Grants Since 2006
PI
Sponsor
Grant #
Start
Stop
Total
Awarded to
Date
Title
MATALON, SADIS
NIH-NHLBI
R01HL75540
12/15/04
11/30/09
$1,406,668
Nitric Oxide Modulation of CFTR Expression and Function
COLLAWN, JAMES F
CYSTIC FIBROSIS
FOUNDATION
COLLAW08PO
12/01/08
11/30/09
$75,000
Cell Biology of CFTR in Polarized Epithelia
CLANCY, JOHN PAUL
INSPIRE
PHARMACEUTICALS, INC
08-110
05/28/08
12/31/09
$55,685
A Phase 3, International, Multi-Center, Randomized, Double-Blind,
Placebo-Controlled, Parallel-Group Efficacy and Safety Study of
Denufosol Tetrasodium Inhalation Solution in Patients with Cystic
Fibrosis Lung Disease and FEV1>= 75% Predicted
GUTIERREZ, HECTOR H
CYSTIC FIBROSIS
FOUNDATION
GUTIER09QI0
01/01/09
12/31/09
$27,000
Early Recognition and intervention for Acute Pulmonary
Exacerbation in CF
ROWE, STEVEN M
VERTEX
PHARMACEUTICALS,
INC.
BERDIEV, BAKHROM K
UNIVERSITY OF
ALABAMA HEALTH
SERVICES FOUNDATION
HARTMAN IV, JOHN L.
COLUMBIA UNIVERSITY /
CYSTIC FIBROSIS
FOUNDATION
SORSCHER, ERIC J
NIH-NIDDK
CLANCY, JOHN PAUL
and
ROWE, STEVEN M
01/01/09
12/31/09
$92,906
NPD Overreading Services for Clinical Trial Entitled "A
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose
Study of VX-809 to Evaluate Safety, Pharmacokinetics, and
Pharmacodynamics of VX-809 in Cystic Fibrosis Subjects
Homozygous for the F508-CFTR Gene Mutation"
______
03/01/07
02/28/10
$216,000
Fluorescence Lifetime-Resolved Imaging: Nanoscale Mapping of
Dynamic Cellular Events (Pursues CFTR/ENaC Interactions)
MILLER08
04/01/08
03/31/10
$94,400
Systematic Genetic and Biochemical Analysis of ER Quality
Control (Designed to determine cellular targets for ΔF508
correction)
P30DK72482
05/01/09
04/30/10
$66,510
UAB CF Research and Translation Core Center - NIDDK
Equipment Supplement
CYSTIC FIBROSIS
FOUNDATION
CLANCY05Y2
01/01/06
04/30/11
$642,688
UAB Cystic Fibrosis National NPD Reading Resource Center Core
CLANCY, JOHN PAUL
CYSTIC FIBROSIS
FOUNDATION
41339119.032
06/01/09
05/31/10
$39,700
A Multi-Center, Phase IIB, Randomized, Placebo-Controlled,
Double-Blind Study of The Effects of N-Acetylcysteine of Redox
Changes and Lung Inflammation in Cystic Fibrosis Patients
(NAC40630)
PYLE, LOUISA
NIH
F30HL096389
06/22/09
06/21/11
$33,450
Potentiation of Mutant CFTR Activity
WOODWORTH,
BRADFORD
AMERICAN ACADEMY OF
OTOLARYNGOLOGY
______
07/01/09
06/30/10
$25,000
Novel Flavonoid Compounds for Cystic Fibrosis Chronic
Rhinosinusitis
VX08-809-101
6
Examples of Active Grants Since 2006
Sponsor
Grant #
Start
Stop
Total
Awarded to
Date
FU, LIANWU (KARL)
AMERICAN LUNG
ASSOCIATION
______
07/01/08
06/30/10
$75,200
Regulation of the Degradation of Cystic Fibrosis Transmembrane
Conductance Regulator under Cystic Fibrosis Conditions
GUTIERREZ, HECTOR H
Cystic Fibrosis Foundation
C001-06
07/01/04
06/30/10
$773,166
Cystic Fibrosis Center for Care, Teaching and Research
6T72MC0000119-01
07/01/09
06/30/10
$332,095
Pediatric Pulmonary Center
FREDER09B0
07/01/09
06/30/10
$48,000
CFF Clinical Fellowship
PI
CLANCY, JOHN PAUL
ROWE, STEVEN M
DHHS - HEALTH
RESOURCES AND
SERVICES
ADMINISTRATION
(MATERNAL AND CHILD
HEALTH BUREAU)
CYSTIC FIBROSIS
FOUNDATION
Title
CLANCY, JOHN PAUL
INSPIRE
PHARMACEUTICALS, INC
08-114
07/13/09
07/12/10
$36,169
Open-Label Extension of Study 08-110 - A Multi-Center Study of
Denufosol Tetrasodium Inhalation Solution in Patients with Cystic
Fibrosis Lung Disease
BENOS, DALE J
NIH-NIDDK
R56DK37206
08/17/09
07/31/10
$362,500
Sodium Entry Into Amiloride-Sensitive Epithelia
BERDIEV, BAKHROM K
NIH - NHLBI
R21HL085112
09/01/08
07/31/10
$412,500
Regulation of Epithelial Sodium Channel by CFTR Chloride
Channel
DELUCAS, LAWRENCE J.
CYSTIC FIBROSIS
FOUNDATION
DELUCA05XXO
08/01/05
07/31/12
$2,063,100
Crystallization and Structure Determination of Full-Length CFTR
Protein
ROWE, STEVEN M
PTC THERAPEUTICS,
INC.
PTC124-GD-009CF
08/05/09
12/31/11
$243,755
Nasal PD Central Reading Services for Clinical Trial Entitled: A
Phase 3 Efficacy and Safety Study of PTC124 as an Oral
Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis
ROWE, STEVEN M
CYSTIC FIBROSIS
FOUNDATION
ROWE08XX0
09/01/08
08/31/10
$25,000
CFTR Activity of Novel F508 Corrector Agents
BROUILLETTE, CHRISTIE
CYSTIC FIBROSIS
FOUNDATION
BROUIL08XXO
09/01/08
08/31/12
$175,755
Expression and purification of CFTR Domain Constructs
CHUNG, WOOK JOON
NIH-NINDS
R21NS067693
09/25/09
08/31/10
$208,358
A Novel HTS Cell-Based Imaging Assay to Identify Chemical
Correctors for F508-CFTR Defects
SCHWIEBERT, ERIK M
NIH-NIDDK
R43 DK084658
09/30/09
08/31/10
$308,000
CF Corrector Ligands Discovered in CF Human Airway Cells
DELUCAS, LAWRENCE J
NIH - NIGMS
R01GM081799
09/15/08
08/31/10
$869,148
Innovative Methods for Membrane Protein Expression and
Crystallization
ROWE, STEVEN M
CYSTIC FIBROSIS
FOUNDATION
ROWE09CS0
10/01/09
09/30/10
$56,841
Special Consultant for Translational Science
7
Examples of Active Grants Since 2006
PI
BROUILLETTE, CHRISTIE
Sponsor
CYSTIC FIBROSIS
FOUNDATION
Grant #
BROUIL07XX0
Start
Stop
Total
Awarded to
Date
11/01/07
10/31/12
$561,202
Recombinant CFTR: Cooperativity of Structural Domains
01/01/08
12/31/10
$60,000
Matrix Metalloproteinase-9 in Pediatric RSV-Induced Respiratory
Failure
Title
CLANCY, JOHN PAUL
KAUL PEDIATRIC
RESEARCH INSTITUTE
ROWE, STEVEN M and
YOUNG, K. RANDALL
CYSTIC FIBROSIS
FOUNDATION
CLANCY09Y0
01/01/07
12/31/11
$1,021,368
ROWE, STEVEN M
MASSACHUSETTS
GENERAL HOSPITAL
323840
01/01/08
12/31/10
$31,900
Development of Optical Coherence Tomography for Measures of
Mucociliary Clearance
CLANCY, JOHN PAUL
VERTEX
PHARMACEUTICALS,
INC.
VX06-770-101
08/29/07
12/31/10
$47,940
Nasal PD Central Reading Services for Study Entitled: A Phase
2a, Randomized, Double-Blind, Placebo-Controlled Study of VX770 t
R56DK056796
02/01/10
01/31/11
$219,750
New Paradigms of CFTR Regulation
R01DK56796
09/01/05
01/31/11
$1,149,353
New Paradigms of CFTR Regulation
ROWE09XX0
03/01/09
02/28/11
$50,000
Ussing Chamber Studies to Characterize CFTR Modulators
03/01/10
02/28/11
$20,000
Assay of Aminoglycosides in a CF Mouse Model
KIRK, KEVIN L
KIRK, KEVIN L
NIH - NATIONAL
INSTITUTE OF DIABETES
& DIGESTIVE & KIDNEY
DISEASES
NIH-NIDDK
ROWE, STEVEN M
CYSTIC FIBROSIS
FOUNDATION
BEDWELL, DAVID M
TECHNION - ISRAEL
INSTITUTE OF
TECHNOLOGY
______
______
UAB Cystic Foundation Therapeutic Development Center
VERTEX
PHARMACEUTICALS,
INC.
VX08-809-101
03/01/09
02/28/11
$98,070
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose
Study of VX-809 to Evaluate Safety, Pharmacokinetics, and
Pharmacodynamics of VX-809 in Cystic Fibrosis Subjects
Homozygous for the F508-CFTR Gene Mutation
ROWE, STEVEN M
PTC THERAPEUTICS,
INC.
PTC124-GD-009CF
03/01/09
02/28/11
$113,422
A Phase 3 Efficacy and Safety Study of PTC124 as an Oral
Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis
GAGGAR, AMIT
CYSTIC FIBROSIS
FOUNDATION
GAGGAR07AO
04/01/07
03/31/11
$254,604
Implications of cross-protease dysregulation in CF
GILEAD SCIENCES, INC.
EA-US-205-0111
05/21/08
05/20/11
$4,000
CLANCY, JOHN PAUL
CLANCY, JOHN PAUL
8
Expanded Access Program for Aztreonam Lysine for Inhalation in
Patients with Cystic Fibrosis and Pseudomonas Aeruginosa
Airway Infection Who Have Limited Treatment Options and are at
Risk for Disease Progression
Examples of Active Grants Since 2006
PI
Sponsor
Grant #
Start
Stop
Total
Awarded to
Date
Title
ROWE, STEVEN M
NIH-NIDDK
R03DK084110
08/25/09
06/30/11
$73,188
Mechanisms Underlying Protein Repair of CFTR Nonsense
Mutations
BLALOCK, J EDWIN
NIH - NATIONAL HEART,
LUNG, AND BLOOD
INSTITUTE
R01HL087824
07/01/09
06/30/11
$411,364
Therapeutics for Chronic Lung Disease: New Antagonists of PGP,
Chemokines and CXCR
GUTIERREZ, HECTOR H
VERTEX
PHARMACEUTICALS,
INC.
VX-08-770-103
07/10/09
07/09/11
$104,765
A Phase 3, 2-Part, Randomized, Double-Blind, PlaceboControlled, Parallel-Group Study to Evaluate the
Pharmacokinetics, Efficacy and Safety of VX-770 in Subjects
Aged 6 to 11Years with Cystic Fibrosis and the G551D Mutation
ROWE, STEVEN M
VERTEX
PHARMACEUTICALS,
INC.
VX-08-770-102
07/10/09
07/09/11
$119,045
A Phase 3, Randomized, Double-Blind, Placebo Controlled,
Parallel Group Study to Evaluate the Efficacy and Safety of VX
770 in Subjects with Cystic Fibrosis and the G551D Mutation
STEELE, CHAD
NIH-UNIVERSITY OF
PITTSBURGH
08/10/09
07/31/11
$109,627
Immune Tolerance and Inflammation in ABPA in Patients with
Cystic Fibrosis
SORSCHER, ERIC J
CYSTIC FIBROSIS
FOUNDATION
SORSCH05X0
09/01/06
08/31/12
$2,019,168
GUTIERREZ, HECTOR H
NIH-NIDDK
P30 DK072482
09/12/09
08/31/11
$204,401
UAB CF Research and Translation Core Center - Pilot
Supplement
ROWE, STEVEN M
NIH-NCRR
UL1RR025777
09/17/09
03/31/12
$500,000
UAB Center for Clinical and Translational Science (CCTS); (ARRA
Supplement (to conduct a multicenter trial of quercetin as an
activator of mutant CFTR)
GUTIERREZ, HECTOR H
ALABAMA DEPARTMENT
OF PUBLIC HEALTH
C00113045
10/01/09
09/30/11
$136,758
Cystic Fibrosis Screening for Newborn Infants
BEDWELL, DAVID M
NIH - NATIONAL
INSTITUTE OF GENERAL
MEDICAL SCIENCES
R01GM06885407S1
12/01/07
11/30/11
$1,038,039
Mechanism of Eukaryotic Translation Termination (Basic studies
to understand mechanism of CFTR truncation alleles)
______
New Reagents for Understanding and Overcoming the Delta-F508
Mutation
CLANCY, JOHN PAUL
KAUL PEDIATRIC
RESEARCH INSTITUTE
______
02/01/10
01/31/12
$50,000
Developing GI Outcome Measures for CFTR Modulator Trials in
Young CF Patients
HARRIS, WILLIAM
THOMAS
KAUL PEDIATRIC
RESEARCH INSTITUTE
______
02/01/10
01/31/12
$30,000
Myofibroblast proliferation in cystic fibrosis: a novel mechanism of
disease modification
9
Examples of Active Grants Since 2006
PI
Sponsor
Start
Stop
Total
Awarded to
Date
Title
CF 2110399
02/08/10
02/07/12
$33,239
A Randomized, Double Blind, Parallel Group, Placebo Controlled
28 Day Study to Investigate the Safety, Tolerability and
Pharmacodynamics of SB-656933 in Patients with Cystic Fibrosis
(CF 2110399)
______
03/01/09
02/28/12
awarded
Bidirectional Transfer of Isolated Primary Airway Cells Obtained
from Lung and Sinus Explants
Grant #
YOUNG, K. RANDALL
GLAXOSMITHKLINE
ROWE, STEVEN M
VERTEX
PHARMACEUTICALS,
INC.
BEDWELL, DAVID M
NIH - NIDDK
P30DK72482
05/01/07
04/30/12
$619,962
UAB CF Research and Translation Core Center - Mouse Models
KIRK, KEVIN L
NIH-NIDDK
P30DK72482
05/01/07
04/30/12
$581,639
Core A: Cell Model and Assay Core
SORSCHER, ERIC J
NIH-NIDDK
P30DK72482
05/01/07
04/30/12
$752,209
UAB CF Research and Translation Core Center - Administrative
Core
ROWE, STEVEN M
NIH - NIDDK
P30DK72482
05/01/07
04/30/12
$389,146
UAB CF Research and Translation Core Center - Clinical Core
ROWE, STEVEN M
CYSTIC FIBROSIS
FOUNDATION
CLANCY 05Y2
01/01/11
04/30/12
$224,062
UAB Center for CFTR Detection
CORMET-BOYAKA,
ESTELLE
AMERICAN LUNG
ASSOCIATION
______
07/01/10
06/30/12
$160,000
Cadmium Alters Regulation of Lung Function via Ion Transport
and Inflammatory Cytokines
KIRK, KEVIN L
NIH-NHLBI
R01HL58341
07/01/07
06/30/12
$978,750
Regulation of CFTR by Syntaxin and N-sec 1 Isoforms
CLINES, GREGORY A.
NIH-NATIONAL
INSTITUTE OF
ARTHRITIS AND
MUSCULOSKELETAL
AND SKIN DISEASES
R21 AR056826
07/01/10
06/30/12
$156,024
CF Bone Disease: Convergence of CFTR and PTH Signaling
BLALOCK, J EDWIN
ALBANY MEDICAL
COLLEGE
SC07-10-001
08/15/08
07/31/12
$188,500
MMP-9 Modulation as an Immunotherapeutic Intervention for
Respiratory Infections
BEBOK, ZSUZSANNA
NIH-NHLBI
R01HL76587
05/01/04
03/31/13
$1,894,192
CHRISTIAN, BECKY
NIH-NCRR
UL1RR025777
05/01/11
04/30/13
$30,000
Making Connections: Improving Quality of Life in Adolescents with
Cystic Fibrosis
PIAZZA, GARY
CYSTIC FIBROSIS
FOUNDATION
R464-CR07
06/01/11
06/30/13
$72,000
Spectral domain optical coherence tomography for the functional
characterization of ion transport modulators
JACKSON, PATRICIA
CYSTIC FIBROSIS
FOUNDATION
R464-CR07
07/01/11
06/30/13
$72,000
Modulation of Small Matrikines by Reactive Aldehydes in CF
10
CFTR Biogenesis and Function in Epithelia
Examples of Active Grants Since 2006
PI
Sponsor
Grant #
Start
Stop
Total
Awarded to
Date
Title
CYSTIC FIBROSIS
FOUNDATION
R464-CR07
07/01/11
06/30/13
$72,000
Analysis of CFTR Post Translational Modification by Mass
Spectrometry
CHILDREN'S HOSPITAL &
REGIONAL MEDICAL
CENTER
346609
07/01/08
12/31/13
$9,164
CF Therapeutics Development Network Individual Project
Schedule #6.0
BLALOCK, J. EDWIN
NIH-NHLBI
R01HL077783
04/01/06
03/31/14
$1,789,648
GUTIERREZ, HECTOR H
CHILDREN'S HOSPITAL &
REGIONAL MEDICAL
CENTER
41339135.032O
04/01/09
03/31/14
$17,694
COLLAWN, JAMES F
NIH-NIDDK
R01DK60065
12/20/02
04/30/14
$1,790,554
ABRAHAM, EDWARD
NIH-NHLBI
R01GM087748
06/01/09
05/31/14
$303,642
WANG, GUANGYU
AMERICAN HEART
ASSOCIATION
______
07/01/10
06/30/14
$77,000
______
12/01/07
12/01/14
$150,000
UAHSF General Endowment Fund Scholar Award for Studies of
CFTR in Sinonasal Epithelial Cells
R01GM095639
09/30/10
07/31/14
$300,000
Production & Crystallization of Membrane Protein for 3D Structure
(includes studies of CFTR)
BARNES, STEPHEN
CLANCY, JOHN PAUL
WOODWORTH,
BRADFORD
DELUCAS, LAWRENCE J
UNIVERSITY OF
ALABAMA HEALTH
SERVICES FOUNDATION
NIH - NATIONAL
INSTITUTE OF GENERAL
MEDICAL SCIENCES
A New Pathway for Neutrophil-Induced Airway Inflammation
The EPIC Observational Study: Longitudinal Assessment of Risk
Factors for and Impact of Pseudomonas Aeruginosa Acquisition
and Early Anti-Pseudomonal Treatment in Children with CF
Cell Biology of CFTR in Polarized Epithelia
HMGB1 and Neutrophil Efferocytosis
Inhibition Mechanisms of the Regulatory Domain in the Cystic
Fibrosis Transmembrane Conductance Regulator
KIRK, KEVIN L
NIH - NATIONAL
INSTITUTE OF DIABETES
& DIGESTIVE & KIDNEY
DISEASES
R01DK056796
02/01/11
01/31/15
$318,638
New Paradigms of CFTR Regulation
GAGGAR, AMIT
NIH-NHLBI
R01HL102371
07/01/10
05/31/15
$377,902
A Novel Proteolytic System of Pulmonary Inflammation.
HOOVER, WYNTON C
DHHS - HEALTH
RESOURCES AND
SERVICES
ADMINISTRATION
(MATERNAL AND CHILD
HEALTH BUREAU)
07/01/10
06/30/15
$365,000
UAB Pediatric Pulmonary Center
T72MC00001
11
Examples of Active Grants Since 2006
PI
Sponsor
Grant #
Start
Stop
Total
Awarded to
Date
Title
SORSCHER, ERIC J
CYSTIC FIBROSIS
FOUNDATION
R464-CR11
07/01/11
06/30/15
$284,000
Research Development Program - Component II
FULLER, CATHERINE M
NIH-NIDDK
R01DK037206
08/01/10
07/31/15
$366,250
Sodium Entry into Amiloride-Sensitive Epithelia
ROWE, STEVEN M
NIH/NATIONAL HEART,
LUNG, BLOOD INSTITUTE
R01HL405487
02/15/11
01/31/16
$367,550
Molecular Pathogenesis and Phenotype of Acquired CFTR
dysfunction in COPD
WOODWORTH,
BRADFORD
NIH - NATIONAL
INSTITUTE OF DENTAL &
CRANIOFACIAL
RESEARCH
K08DE021426
03/01/11
02/29/16
$133,596
Chloride Secretagogues for Acquired CFTR Dysfunction in
Chronic Rhinosinusitis
BEDWELL, DAVID M
TECHNION - ISRAEL
INSTITUTE OF
TECHNOLOGY
04/01/11
03/31/16
$134,677
Tuning aminoglycosides for treatment of genetic diseases
R01 GM094792
(subcontract)
Total for the above awarded grants =
consists of:
NIH funding =
CFF/CFFT funding =
All other sponsors =
Anesthesiology
Cell Biology
Chemistry
Genetics
Medicine
Microbiology
Neurobiology
$28,814,579
$10,001,238
$7,218,060
$46,033,877
$46,033,877
62.59%
21.73%
15.68%
100.00%
Interdisciplinary Departments represented by the above
Principle Investigators:
(Ji, Matalon)
(Bebok, Berdiev, Collawn,
Fu, Sztul)
(Brouillette)
(Guimbellot, Hartman, Pyle)
(Blalock, Clines, Gaggar,
Liu, Rowe, Sorscher,
Steele)
(Bedwell, Yother)
(Chung)
Nursing
(Christian)
Optometry
(Delucas)
Pediatrics
Pharmacology
Physiology & Biophysics
(Clancy, Gutierrez, Harris)
(Falany)
(Benos, Kirk, Schwiebert)
Public Health
(Fannuchi)
Surgery
(Woodworth)
Updated 2nd Quarter, 2011
12